Table 1.
Participant Characteristics
| Age (years) | Unexposed (n = 20) |
COVID-19 (n = 20) |
|---|---|---|
| 20–66 (median = 31, IQR = 21) | 20–64 (median = 44, IQR = 9) | |
| Gender | ||
| Male (%) | 35% (7/20) | 45% (9/20) |
| Female (%) | 65% (13/20) | 55% (11/20) |
| Residency | ||
| California (%) | 95% (19/20) | 100% (20/20) |
| USA, Non-California (%) | 5% (1/20) | 0% (0/20) |
| Sample Collection Date | March 2015–March 2018 | March–April 2020 |
| SARS-CoV-2 PCR Positivity | N/A | 100% (16/16 tested) |
| Antibody Test Positivitya | N/A | 90% (18/20) |
| Disease Severityb | ||
| Mild | N/A | 70% (14/20) |
| Moderate | N/A | 20% (4/20) |
| Severe | N/A | 10% (2/20) |
| Critical | N/A | 0% (0/20) |
| Symptoms | ||
| Cough | N/A | 79% (15/19) |
| Fatigue | N/A | 42% (8/19) |
| Fever | N/A | 37% (7/19) |
| Anosmia | N/A | 21% (4/19) |
| Dyspnea | N/A | 16% (3/19) |
| Diarrhea | N/A | 5% (1/19) |
| Days Post Symptom Onset at Collection | N/A | 20–36 (18/20) (median = 26, IQR = 7) |
| Past Medical History | ||
| No known | N/A | 65% (13/20) |
| Hyperlipidemia | N/A | 15% (3/20) |
| Hypertension | N/A | 10% (2/20) |
| Asthma | N/A | 10% (2/20) |
| Known or suspected sick contact/exposure | N/A | 75% (15/20) |
a
Commercial skin prick lateral flow assay.
b
WHO criteria.